SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dynavax DVAX -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (110)6/14/2013 1:39:15 PM
From: mopgcw  Read Replies (1) | Respond to of 184
 
personally added a significant chunk again here; fwiw. the nuisance lawsuits started as to be expected. but if they get the safety data, large upside. downside is lose $1/share from here. nice risk/reward in my calc.



To: The Ox who wrote (110)6/14/2013 2:03:41 PM
From: fred hayes  Respond to of 184
 
I thought it was cheap in the $1.70's. I can't see fda killing Heplisav with requiring trials so big that dvax can't afford it. But I've been dead wrong so far...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News